Cellectis S.A.
CLLS- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001627281
No open-market purchases or sales by Cellectis S.A. insiders were filed in the last 90 days; 27 institutions reported holding it in 13F filings for Q2 2026, worth $28.4M in total; no superinvestor holds it.
Q3 2022 vs. Q2 2022
How the institutions holding Cellectis S.A. changed between Q2 2022 and Q3 2022.
All holders in Q3 2022All holders in Q2 2022
| Measure | Q2 2022 | Q3 2022 | Change |
|---|---|---|---|
| Holders | 45 | 50 | +5 |
| Shares | 10.8M | 10.3M | −530.7K (−4.9%) |
| Value | $30.6M | $23.6M | −$7.01M (−22.9%) |
New holders (9)
Institutions that held Cellectis S.A. at the end of Q3 2022 but not at the end of Q2 2022.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Woodline Partners LP | 169,802 | $389.0K | 0.01% |
| Kettle Hill Capital Management, LLC | 104,596 | $240.0K | 0.06% |
| Vanguard Group Inc | 85,864 | $197.0K | 0.00% |
| Baird Financial Group, Inc. | 32,640 | $74.0K | 0.00% |
| Balyasny Asset Management LLC | 18,352 | $42.0K | 0.00% |
| Two Sigma Investments, LP | 13,303 | $30.0K | 0.00% |
| SEI Investments Co | 10,977 | $25.0K | 0.00% |
| Barclays PLC | 650 | $1.00K | 0.00% |
| China Universal Asset Management Co., Ltd. | 168 | $0 | 0.00% |
Sold out (4)
Institutions that held Cellectis S.A. at the end of Q2 2022 and filed for Q3 2022 without it.
| Institution | Shares, Q2 2022 | Value, Q2 2022 |
|---|---|---|
| Bpifrance SA | 425,726 | $1.21M |
| Virtu Financial LLC | 16,366 | $46.0K |
| BNP Paribas Arbitrage, SA | 229 | $648 |
| Toronto Dominion Bank | 31 | $0 |